

December 5, 2023

Rasmus Holm-Jorgensen  
Chief Financial Officer  
Acrivon Therapeutics, Inc.  
480 Arsenal Way, Suite 100  
Watertown, Massachusetts 02472

Therapeutics, Inc.  
Statement on Form S-3  
2023

Re: Acrivon  
Registration  
Filed December 1,  
File No. 333-275854

Dear Rasmus Holm-Jorgensen:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tamika Sheppard at 202-551-8346 with any questions.

Sincerely,

Division of Corporation Finance

Office of Life Sciences

cc:

Archer Rubin